Tragiannidis Athanasios, Linke Christina, Correa-Martinez Carlos L, Herbrüggen Heidrun, Schaumburg Frieder, Groll Andreas H
Infectious Disease Research Program, Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology, Children's University Hospital Münster, 48149 Münster, Germany.
2nd Department of Pediatrics, Aristotle University of Thessaloniki, AHEPA Hospital, 54636 Thessaloniki, Greece.
J Fungi (Basel). 2023 Jan 24;9(2):157. doi: 10.3390/jof9020157.
Several studies have evaluated the serum galactomannan (GM) antigen assay in pediatric patients, and there is convincing evidence for its usefulness as a diagnostic tool for invasive infections in patients with acute leukemias or post allogeneic hematopoietic cell transplantation (HCT). Less is known about the utility of the assay in monitoring responses to treatment in patients with established invasive aspergillosis (IA). Here, we present the long-term kinetics of serum galactomannan in two severely immunocompromised adolescents with invasive pulmonary aspergillosis (IPA) who were cured after complicated clinical courses. We also review the utility of the GM antigen assay in serum as a prognostic tool around the time of diagnosis of IA and as a biomarker to monitor disease activity in patients with established IA and assess responses to systemic antifungal therapy.
多项研究评估了血清半乳甘露聚糖（GM）抗原检测在儿科患者中的应用，有令人信服的证据表明其可作为急性白血病或异基因造血细胞移植（HCT）后患者侵袭性感染的诊断工具。对于该检测在监测已确诊侵袭性曲霉病（IA）患者治疗反应中的效用，了解较少。在此，我们展示了两名患有侵袭性肺曲霉病（IPA）的严重免疫功能低下青少年患者血清半乳甘露聚糖的长期动力学变化，这两名患者在经历复杂临床病程后治愈。我们还回顾了GM抗原检测在血清中作为IA诊断时的预后工具以及作为监测已确诊IA患者疾病活动和评估全身抗真菌治疗反应的生物标志物的效用。
